CanSino Biologics Inc. (HKG:6185)
Hong Kong
· Delayed Price · Currency is HKD 29.84
-2.20 (-6.87%)
Apr 29, 2026, 4:08 PM HKT
CanSino Biologics Employees
CanSino Biologics had 1,115 employees as of June 30, 2025. The number of employees increased by 10 or 0.90% since the number was reported on December 31, 2024.
Employees
1,115
Change
10
Growth
0.90%
Revenue / Employee
1.05M HKD
Profits / Employee
27.35K HKD
Market Cap
12.90B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Consun Pharmaceutical Group | 3,115 |
| Sihuan Pharmaceutical Holdings Group | 2,843 |
| Luye Pharma Group | 5,115 |
| Shandong Xinhua Pharmaceutical Company | 7,240 |
| The United Laboratories International Holdings | 18,000 |
| China Traditional Chinese Medicine Holdings Co. | 14,846 |
| Grand Pharmaceutical Group | 12,614 |
| China Shineway Pharmaceutical Group | 2,867 |
CanSino Biologics News
- 7 weeks ago - Meningitis Shot Delivers Dose Of Good Cheer For CanSino - Benzinga
- 2 months ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 4 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire